Developer docs
API playgroundTry for free, no card

Search company profiles

TetraLogic Pharmaceuticals

Full company profile

uuid0036mp1

Namestring
TetraLogic Pharmaceuticals
Company typeenum
Public
Founded yearint
2001
Descriptiontext

TetraLogic Pharmaceuticals is a U.S.-based, clinical-stage biopharmaceutical company founded in 2001 and headquartered in Malvern, Pennsylvania. Per the firm's stated positioning, it discovers and develops small-molecule drugs intended to treat debilitating diseases and conditions. In the available source material, no specific drug candidates, approved products, or therapeutic offerings have been identified — the company is described at the platform/category level only. Its operating footprint is small (11–50 employees), and the public profile surfaces a dedicated Regulatory Affairs and Quality Control capability under named leadership, with John M. Gill as CEO and Sherri Carenzo as Head of Regulatory Affairs and Quality Control Manager.

The capital history shows a venture-backed clinical developer that completed multiple Series 2 and Series 3 financings between 2006 and 2011 — led primarily by Clarus Ventures with Latterell Venture Partners co-leading the Series 2 and a broad investor syndicate including Amgen Ventures, Pfizer Venture Investments, HealthCare Ventures, Hatteras Venture Partners, Quaker BioVentures, Novitas Capital, The Vertical Group, and Nextech Invest — for total disclosed private funding of roughly $164M. The company subsequently expanded its pipeline in April 2014 by acquiring Shape Pharmaceuticals for $13M and raised an additional $47M in June 2014. It is publicly traded on OTC Markets under ticker TLOG (otcpink:TLOG).

The financial profile disclosed through 2015 shows no revenue line item, with operating losses reported annually in the $17–38M range and net losses reaching roughly $50M in 2015 — consistent with a pre-commercial drug developer fully funded by equity capital rather than product cash flow. The combination of persistent cash burn, small headcount, no disclosed revenue, and migration to the OTC pink sheets (rather than a major exchange) is consistent with a company that is operating but financially constrained, with no visible mechanism for near-term commercialization absent a partnership, licensing deal, or capital event not present in the source data.

Short descriptiontext

TetraLogic Pharmaceuticals is a U.S. clinical-stage biopharmaceutical company founded in 2001 that discovers and develops small-molecule drugs targeting debilitating diseases, operating with 11–50 employees and trading on OTC pink sheets as TLOG.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMalvern, United States
HQ citystring
Malvern
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
small molecule therapeutics, biopharmaceutical drug discovery, clinical stage development, pharmaceutical research, debilitating disease treatments
Industry1 code
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biopharmaceuticals — Small Molecule Therapeutics
Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

TetraLogic Pharmaceuticals is a biopharmaceutical company that discovers and develops small molecule drugs intended for the treatment of debilitating diseases and conditions. The company operates as a development-stage firm with no reported product revenue between 2011 and 2015, generating value through internal R&D and acquisitions such as Shape Pharmaceuticals.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

TetraLogic Pharmaceuticals is a biopharmaceutical company. Based on the available source data, no specific pharmaceutical products, drug candidates, or therapeutic offerings have been identified. The company is publicly traded on the OTCMKTS exchange under ticker symbol TLOG and has been the subject of comparative financial analyses with other biopharmaceutical firms such as Arcutis Biotherapeutics.

Product and service2 records
1Small Molecule Therapeutics Pipeline
CategoryBiopharmaceuticals — Small Molecule Therapeutics
Description

Pipeline of small molecule drug candidates intended for the treatment of debilitating diseases and conditions; no specific branded products or approved drugs are named in the source data, and the company reported no revenue from 2011–2015, consistent with a development-stage offering.

2Shape Pharmaceuticals Asset Portfolio
CategoryBiopharmaceuticals — Small Molecule Therapeutics
Description

Drug development assets acquired through the 2014 acquisition of Shape Pharmaceuticals, integrated into TetraLogic's small-molecule research and development pipeline for debilitating diseases.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing small-molecule drugs targeting cancer stem cells. Closely comparable in scale, small-molecule modality, oncology focus, and small-cap public-company structure.

2MEI Pharma
TypeDirect peer
Description

Late-stage clinical biopharmaceutical company developing small-molecule oncology drugs. Comparable in business model, small-molecule focus, capital intensity, and small public-company scale.

3Forma Therapeutics
TypeEmerging player
Description

Clinical-stage biopharmaceutical company developing small-molecule therapies for rare hematologic diseases and cancers. Comparable in small-molecule platform approach and clinical-stage scale.

TypeDirect peer
Description

Small-cap clinical-stage biopharmaceutical company developing innovative therapeutics for serious skin diseases. Directly cited in TetraLogic's own comparative financial analysis as a benchmark peer, with comparable scale and small-molecule/specialty-pharma profile.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing small-molecule therapeutics targeting cancer. Highly comparable in small-molecule modality, oncology focus, and clinical-stage small-cap public-company profile.

TypeDirect peer
Description

Clinical-stage immuno-oncology company developing small-molecule and biologic therapeutics for serious diseases. Comparable in size, clinical-stage structure, and oncology/specialty pharma focus.

TypeDirect peer
Description

Clinical-stage pharmaceutical company developing small-molecule therapies for cancer and other serious diseases. Comparable in modality, therapeutic area, and small-cap clinical-stage profile.

TypeEmerging player
Description

Clinical-stage biopharmaceutical company developing small-molecule epigenetic therapies for cancer and other serious diseases. Comparable in modality, therapeutic-area focus, and small-cap clinical-stage scale.

TypeDirect peer
Description

Developer of small-molecule kinase inhibitors for oncology with similar small-cap public-company profile, clinical-stage structure, and targeted-therapy approach to debilitating diseases.

TypeDirect peer
Description

Clinical-stage small-molecule oncology drug developer with a similar small-cap, loss-making, public-company profile and focus on targeted therapeutics for serious diseases.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TetraLogic Pharmaceuticals

Biopharmaceuticals — Small Molecule Therapeuticstetralogicpharma.com

TetraLogic Pharmaceuticals is a U.S. clinical-stage biopharmaceutical company founded in 2001 that discovers and develops small-molecule drugs targeting debilitating diseases, operating with 11–50 employees and trading on OTC pink sheets as TLOG.

What TetraLogic Pharmaceuticals does

TetraLogic Pharmaceuticals is a U.S.-based, clinical-stage biopharmaceutical company founded in 2001 and headquartered in Malvern, Pennsylvania. Per the firm's stated positioning, it discovers and develops small-molecule drugs intended to treat debilitating diseases and conditions. In the available source material, no specific drug candidates, approved products, or therapeutic offerings have been identified — the company is described at the platform/category level only. Its operating footprint is small (11–50 employees), and the public profile surfaces a dedicated Regulatory Affairs and Quality Control capability under named leadership, with John M. Gill as CEO and Sherri Carenzo as Head of Regulatory Affairs and Quality Control Manager.

The capital history shows a venture-backed clinical developer that completed multiple Series 2 and Series 3 financings between 2006 and 2011 — led primarily by Clarus Ventures with Latterell Venture Partners co-leading the Series 2 and a broad investor syndicate including Amgen Ventures, Pfizer Venture Investments, HealthCare Ventures, Hatteras Venture Partners, Quaker BioVentures, Novitas Capital, The Vertical Group, and Nextech Invest — for total disclosed private funding of roughly $164M. The company subsequently expanded its pipeline in April 2014 by acquiring Shape Pharmaceuticals for $13M and raised an additional $47M in June 2014. It is publicly traded on OTC Markets under ticker TLOG (otcpink:TLOG).

The financial profile disclosed through 2015 shows no revenue line item, with operating losses reported annually in the $17–38M range and net losses reaching roughly $50M in 2015 — consistent with a pre-commercial drug developer fully funded by equity capital rather than product cash flow. The combination of persistent cash burn, small headcount, no disclosed revenue, and migration to the OTC pink sheets (rather than a major exchange) is consistent with a company that is operating but financially constrained, with no visible mechanism for near-term commercialization absent a partnership, licensing deal, or capital event not present in the source data.

TetraLogic Pharmaceuticals firmographics

Firmographics
Name
TetraLogic Pharmaceuticals
Website
https://tetralogicpharma.com
Company type
Public
Founded year
2001
Operating status
Operating
Headcount range
11–50 employees
Short description
TetraLogic Pharmaceuticals is a U.S. clinical-stage biopharmaceutical company founded in 2001 that discovers and develops small-molecule drugs targeting debilitating diseases, operating with 11–50 employees and trading on OTC pink sheets as TLOG.
Ownership category
akta.pro rank

TetraLogic Pharmaceuticals industry classification

Industry
Product category
Biopharmaceuticals — Small Molecule Therapeutics
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Small molecule therapeutics
  • Biopharmaceutical drug discovery
  • Clinical stage development
  • Pharmaceutical research
  • Debilitating disease treatments

Where TetraLogic Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Malvern
HQ country
United States
HQ region
North America

Markets served

TetraLogic Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

TetraLogic Pharmaceuticals product offering

Product offering

Core offering

TetraLogic Pharmaceuticals is a biopharmaceutical company that discovers and develops small molecule drugs intended for the treatment of debilitating diseases and conditions. The company operates as a development-stage firm with no reported product revenue between 2011 and 2015, generating value through internal R&D and acquisitions such as Shape Pharmaceuticals.

Product overview

TetraLogic Pharmaceuticals is a biopharmaceutical company. Based on the available source data, no specific pharmaceutical products, drug candidates, or therapeutic offerings have been identified. The company is publicly traded on the OTCMKTS exchange under ticker symbol TLOG and has been the subject of comparative financial analyses with other biopharmaceutical firms such as Arcutis Biotherapeutics.

Differentiator

Problem solved

Functional benefit

Products and services

  • Small Molecule Therapeutics Pipeline Pipeline of small molecule drug candidates intended for the treatment of debilitating diseases and conditions; no specific branded products or approved drugs are named in the source data, and the company reported no revenue from 2011–2015, consistent with a development-stage offering.
  • Shape Pharmaceuticals Asset Portfolio Drug development assets acquired through the 2014 acquisition of Shape Pharmaceuticals, integrated into TetraLogic's small-molecule research and development pipeline for debilitating diseases.

Companies that use TetraLogic Pharmaceuticals

Customer profile

Ideal customer profiles1 record

TetraLogic Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

TetraLogic Pharmaceuticals partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves6 records

Expansion highlights3 records

TetraLogic Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Verastem: Clinical-stage biopharmaceutical company developing small-molecule drugs targeting cancer stem cells. Closely comparable in scale, small-molecule modality, oncology focus, and small-cap public-company structure.
  • MEI Pharma: Late-stage clinical biopharmaceutical company developing small-molecule oncology drugs. Comparable in business model, small-molecule focus, capital intensity, and small public-company scale.
  • Arcutis Biotherapeutics: Small-cap clinical-stage biopharmaceutical company developing innovative therapeutics for serious skin diseases. Directly cited in TetraLogic's own comparative financial analysis as a benchmark peer, with comparable scale and small-molecule/specialty-pharma profile.
  • Aprea Therapeutics: Clinical-stage biopharmaceutical company developing small-molecule therapeutics targeting cancer. Highly comparable in small-molecule modality, oncology focus, and clinical-stage small-cap public-company profile.
  • Trillium Therapeutics: Clinical-stage immuno-oncology company developing small-molecule and biologic therapeutics for serious diseases. Comparable in size, clinical-stage structure, and oncology/specialty pharma focus.
  • Karyopharm Therapeutics: Clinical-stage pharmaceutical company developing small-molecule therapies for cancer and other serious diseases. Comparable in modality, therapeutic area, and small-cap clinical-stage profile.
  • Deciphera Pharmaceuticals: Developer of small-molecule kinase inhibitors for oncology with similar small-cap public-company profile, clinical-stage structure, and targeted-therapy approach to debilitating diseases.
  • Curis: Clinical-stage small-molecule oncology drug developer with a similar small-cap, loss-making, public-company profile and focus on targeted therapeutics for serious diseases.

Emerging players

  • Forma Therapeutics: Clinical-stage biopharmaceutical company developing small-molecule therapies for rare hematologic diseases and cancers. Comparable in small-molecule platform approach and clinical-stage scale.
  • Constellation Pharmaceuticals: Clinical-stage biopharmaceutical company developing small-molecule epigenetic therapies for cancer and other serious diseases. Comparable in modality, therapeutic-area focus, and small-cap clinical-stage scale.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

TetraLogic Pharmaceuticals social profiles

Digital presence

TetraLogic Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TetraLogic Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles2 records

TetraLogic Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TetraLogic Pharmaceuticals M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TetraLogic Pharmaceuticals

What does TetraLogic Pharmaceuticals do?

TetraLogic Pharmaceuticals is a biopharmaceutical company that discovers and develops small molecule drugs intended for the treatment of debilitating diseases and conditions. The company operates as a development-stage firm with no reported product revenue between 2011 and 2015, generating value through internal R&D and acquisitions such as Shape Pharmaceuticals.

Is TetraLogic Pharmaceuticals a public or private company?

TetraLogic Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was TetraLogic Pharmaceuticals founded?

TetraLogic Pharmaceuticals was founded in 2001. It employs 11 to 50 people.

Where is TetraLogic Pharmaceuticals based?

TetraLogic Pharmaceuticals is headquartered in Malvern, United States, in the North America region.

Who are TetraLogic Pharmaceuticals's main competitors?

Direct peers on record are Verastem, MEI Pharma, Arcutis Biotherapeutics, Aprea Therapeutics, Trillium Therapeutics, Karyopharm Therapeutics, Deciphera Pharmaceuticals and Curis. Emerging players are Forma Therapeutics and Constellation Pharmaceuticals.

Does TetraLogic Pharmaceuticals have an API?

No public API is recorded for TetraLogic Pharmaceuticals.

What industry is TetraLogic Pharmaceuticals in?

TetraLogic Pharmaceuticals's product category is Biopharmaceuticals — Small Molecule Therapeutics. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Defense WorldAnalyzing Arcutis Biotherapeutics (NASDAQ:ARQT) & TetraLogic Pharmaceuticals (OTCMKTS:TLOG)This article presents a comparative financial analysis of Arcutis Biotherapeutics (NASDAQ:ARQT) and TetraLogic Pharmaceuticals (OTCMKTS:TLOG), two biopharmaceutical companies, evaluating them across ten factors including dividends, profitability, analyst ratings, valuation, and risk metrics. The analysis finds that TetraLogic Pharmaceuticals outperforms Arcutis Biotherapeutics on six of the ten comparison factors. Arcutis Biotherapeutics currently has a consensus target price of $34.00, representing a potential upside of 38.61%, and holds a stronger analyst rating score of 2.50 compared to TetraLogic's 0.00.PR NewswireMedivir 2020 Annual Report publishedMedivir AB announced the publication of its 2020 Annual Report, highlighting key developments including promising phase Ia study data for its liver cancer drug candidate MIV-818 and subsequent initiation of phase Ib study. The company also renegotiated its birinapant agreement with TetraLogic and signed a license agreement with IGM Biosciences in January 2021 for the development of birinapant in combination with IGM-antibodies for solid tumors. Additionally, Medivir completed a financing round with strong support from existing investors and new specialist investors, expanding its institutional ownership base.PR NewswireMedivir - Invitation to Conference Call and WebcastMedivir AB announced it will host an analyst and investor conference call on January 9, 2017, to present further financial aspects of oncology programs acquired from TetraLogic Pharmaceuticals Corporation. The call will cover clinical stage compounds remetinostat and birinapant, with CEO Niklas Prager, CFO Ola Burmark, and CSO Richard Bethell presenting.GlobeNewswireTetraLogic Pharmaceuticals Corporation Announces Completion of Sale of SMAC Mimetic and HDAC Inhibitor Assets to Medivir ABTetraLogic completed the sale of its SMAC mimetic and HDAC inhibitor assets to Medivir for $12 million in cash plus up to $153 million in milestones and earn-outs. The company will use the cash to redeem $12 million in senior notes and has delisted its stock.PR NewswireImpax Announces Appointment of J. Kevin Buchi to Board of DirectorsImpax Laboratories, Inc. announced on November 23, 2016, the appointment of J. Kevin Buchi to its Board of Directors. Buchi brings over two decades of pharmaceutical executive experience, having previously served as CEO of Cephalon (acquired by Teva in 2011) and most recently as President and CEO of TetraLogic Pharmaceuticals Corporation. The appointment is expected to provide the board with insights on operations, strategy, and corporate governance.PR NewswireMyelodysplastic Syndrome Market to Grow at 10% CAGR to 2019The global myelodysplastic syndrome drug market is forecast to grow at a 10% CAGR from 2015 to 2019. Growth is driven by diagnostic tools, unmet medical needs, and an aging population, with the Americas expected to dominate. High drug costs may deter some patients.LifescivcTrophies for the biggest biotech venture financings? - LifeSciVCThe author questions whether raising large biotech rounds is a virtue, citing Pacific Biosciences and Complete Genomics as examples. He argues that high capital intensity may impair returns, and suggests a capital-efficiency list would be useful.GlobeNewswireTetraLogic Announces Pricing of $25 Million Public OfferingTetraLogic Pharmaceuticals priced an underwritten public offering of 6.25 million shares at $4.00 per share, expected to close May 6, 2015. The offering will generate gross proceeds of $25 million, with net proceeds of approximately $23 million after expenses. Proceeds will be used for general corporate purposes, including working capital and pipeline development.GlobeNewswireTetraLogic Announces Public Offering of Common StockTetraLogic Pharmaceuticals commenced an underwritten public offering of common stock, with William Blair and Nomura as joint book-running managers. The company intends to use net proceeds for general corporate purposes, including working capital, pipeline development, and acquisitions. The offering is subject to market conditions and may not be completed.GlobeNewswireTetraLogic Pharmaceuticals Announces Preclinical Data Indicating Birinapant's Breadth of Activity in Models of Infectious DiseaseTetraLogic Pharmaceuticals announced preclinical data from a collaboration with the Walter and Eliza Hall Institute showing birinapant reduces viral burden in HBV-infected mice and shows activity in HIV and tuberculosis models. The company entered a worldwide exclusive license agreement for a patent on treating intracellular infections with IAP inhibitors. Clinical studies are planned based on this work.